Pharmaceuticals

Global Inhalation CDMO Market Valuation and Growth Prospects: $8.95 Billion by 2029

December 3, 2025 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the inhalation cdmo market from 2025–2034 with trusted insights from The Business Research Company

What Are The Future Growth Projections For The Inhalation CDMO Market Size?

The roxadustat market size has seen robust expansion in recent years. It is anticipated to grow from $6.44 billion in 2024 to $6.86 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 6.5%. The historical growth can be linked to regulatory clearances in major markets, compelling clinical trial results, the rising incidence of chronic kidney disease, increased understanding of anemia management, and governmental assistance for anemia therapies.

The roxadustat market is anticipated to experience substantial expansion over the upcoming years. It is projected to reach $8.95 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.9%. This projected growth stems from factors such as continuous research into novel indications, rising healthcare spending, a need for non-injectable treatments for anemia, broadening reimbursement strategies, and an expanding elderly demographic. Key developments anticipated during this period encompass a move towards oral anemia therapies, heightened competition from alternative treatments, an increase in licensing collaborations, greater investment in hypoxia-inducible factor research, and an emphasis on patient-focused treatment methods.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21280&type=smp

What Core Market Drivers Are Expanding The Inhalation CDMO Industry?

The increasing prevalence of individuals suffering from chronic kidney disease (CKD) is anticipated to boost the expansion of the Roxadustat market in the future. CKD is a persistent ailment where kidney function progressively deteriorates, potentially culminating in kidney failure without intervention. A global surge in CKD patients is observed, attributed to an aging populace, escalating cases of diabetes, hypertension, and detrimental lifestyle choices. Roxadustat aids in the management of chronic kidney disease by prompting erythropoietin synthesis, which, in turn, enhances red blood cell generation, counteracting anemia frequently linked with the condition, and thus elevating patients’ kidney function and life quality. As an illustration, a December 2024 report from the Australian Institute of Health and Welfare (AIHW), an Australian government body, indicated that chronic kidney disease mortality rates saw a slight annual increase, specifically 4.2% in 2021 and 6.2% in 2022. Consequently, the growing count of people with chronic kidney disease (CKD) is fueling the development of the Roxadustat market.

What Segment Insights Are Highlighted In The Inhalation CDMO Market Report?

The roxadustat market covered in this report is segmented –

1) By Type: 20mg, 50mg

2) By Product Formulation: Oral Tablets

3) By Distribution Channel: Hospitals, Specialty Pharmacies, Dialysis Centers

4) By End-User Application: Chronic Kidney Disease-Associated Anemia, Other Anemia Conditions

Which Notable Trends Are Transforming The Inhalation CDMO Market Outlook?

Key companies active in the Roxadustat market are opting for reimbursement through the high-tech drugs scheme. This approach aims to expand patient access by lowering financial barriers, thereby accelerating market adoption and demonstrating the economic value of their innovative therapies. The high-tech drugs scheme is a government-administered program predominantly in Ireland, which provides coverage for the dispensing of costly, highly specialized medications typically prescribed in hospital settings. For example, in September 2022, Astellas Pharma Company Ltd., a US-based pharmaceutical company, announced that its EVRENZO (Roxadustat) had been granted reimbursement under the High-Tech Drugs Scheme in Ireland. Roxadustat is the first orally administered hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitor of its class to be licensed and reimbursed in Ireland. Clinical findings showed Roxadustat was effective in achieving and maintaining target hemoglobin levels (10-12g/dL) in patients with symptomatic anemia of CKD, regardless of their dialysis status or previous ESA treatment.

Which Firms Are Driving Innovation Within The Inhalation CDMO Market?

Major companies operating in the roxadustat market are AstraZeneca PLC, Viatris Inc., Astellas Pharma Inc., Dr. Reddy’s Laboratories Ltd., Hetero Drugs Limited, Akebia Therapeutics Inc., Metrochem API Private Limited, FibroGen Inc., AMI Lifesciences, Lee Pharma Ltd., Faran Shimi Pharmaceutical Company, Maithri Drugs Pvt. Ltd., Clearsynth Labs Ltd., Bal Pharma, HEMA Pharmaceuticals Pvt. Ltd., Zhejiang Hengkang Pharmaceutical Co. Ltd., Kimia Biosciences Pvt. Ltd., Lewens Labs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., GLR Innovations, Suzhou Biosyntech Co. Ltd., Shanvr Life Sciences Pvt. Ltd.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/roxadustat-global-market-report

What Regional Trends Are Shaping Growth In The Inhalation CDMO Market?

North America was the largest region in the Roxadustat market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the roxadustat market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=21280&type=smp

Browse Through More Reports Similar to the Global Inhalation CDMO Market 2025, By The Business Research Company

Anemia And Other Blood Disorder Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Chemotherapy Induced Anemia Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report

Diabetic Kidney Disease Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/diabetic-kidney-disease-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795